AvertD Post-Approval Study for Opioid Use Disorder
This study is looking at a genetic test called AvertD. This test helps determine the likelihood of developing Opioid Use Disorder (OUD) before someone is prescribed opioids. The study wants to see how well AvertD works (its sensitivity and specificity) over five years. You might be able to join if you are 18 or older, have not received an opioid prescription before, and are being considered for your first oral opioid prescription within 4 to 30 days. You must also be willing to complete yearly assessments for five years and have AvertD prescribed as part of your care. The current recruitment status is unclear.
- Study design
- This is an observational study planning to enroll 4000 participants. It is not specified if it is randomized or blinded.
- What's involved
- You would need to complete yearly assessments for 5 years. You must also have AvertD prescribed as part of your care.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for 5 years to measure the sensitivity and specificity of AvertD.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
AvertD Post-Approval Study
At a glance
Conditions
Where it's being run
1 sites across 1 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Sensitivity and Specificity of AvertDMeasured over 5 years
Comparison of Averted results to diagnosis of Opioid Used Disorder from M.I.N.I. tool